319 related articles for article (PubMed ID: 29946150)
1. Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing.
Gerhart SV; Kellner WA; Thompson C; Pappalardi MB; Zhang XP; Montes de Oca R; Penebre E; Duncan K; Boriack-Sjodin A; Le B; Majer C; McCabe MT; Carpenter C; Johnson N; Kruger RG; Barbash O
Sci Rep; 2018 Jun; 8(1):9711. PubMed ID: 29946150
[TBL] [Abstract][Full Text] [Related]
2. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
AbuHammad S; Cullinane C; Martin C; Bacolas Z; Ward T; Chen H; Slater A; Ardley K; Kirby L; Chan KT; Brajanovski N; Smith LK; Rao AD; Lelliott EJ; Kleinschmidt M; Vergara IA; Papenfuss AT; Lau P; Ghosh P; Haupt S; Haupt Y; Sanij E; Poortinga G; Pearson RB; Falk H; Curtis DJ; Stupple P; Devlin M; Street I; Davies MA; McArthur GA; Sheppard KE
Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17990-18000. PubMed ID: 31439820
[TBL] [Abstract][Full Text] [Related]
3. Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery.
Bezzi M; Teo SX; Muller J; Mok WC; Sahu SK; Vardy LA; Bonday ZQ; Guccione E
Genes Dev; 2013 Sep; 27(17):1903-16. PubMed ID: 24013503
[TBL] [Abstract][Full Text] [Related]
4. Deletion of RBMX RGG/RG motif in Shashi-XLID syndrome leads to aberrant p53 activation and neuronal differentiation defects.
Cai T; Cinkornpumin JK; Yu Z; Villarreal OD; Pastor WA; Richard S
Cell Rep; 2021 Jul; 36(2):109337. PubMed ID: 34260915
[TBL] [Abstract][Full Text] [Related]
5. PRPF19 regulates p53-dependent cellular senescence by modulating alternative splicing of MDM4 mRNA.
Yano K; Takahashi RU; Shiotani B; Abe J; Shidooka T; Sudo Y; Yamamoto Y; Kan S; Sakagami H; Tahara H
J Biol Chem; 2021 Jul; 297(1):100882. PubMed ID: 34144037
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition.
Bedard GT; Gilaj N; Peregrina K; Brew I; Tosti E; Shaffer K; Tyler PC; Edelmann W; Augenlicht LH; Schramm VL
J Biol Chem; 2024 Jan; 300(1):105492. PubMed ID: 38000655
[TBL] [Abstract][Full Text] [Related]
7. Identification and expression of a novel MDM4 splice variant in human glioma.
Wang X; Sheng P; Guo X; Wang J; Hou L; Hu G; Luo C; Dong Y; Lu Y
Brain Res; 2013 Nov; 1537():260-6. PubMed ID: 23994448
[TBL] [Abstract][Full Text] [Related]
8. A genome-wide siRNA screen for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment.
Siebring-van Olst E; Blijlevens M; de Menezes RX; van der Meulen-Muileman IH; Smit EF; van Beusechem VW
Mol Oncol; 2017 May; 11(5):534-551. PubMed ID: 28296343
[TBL] [Abstract][Full Text] [Related]
9. Selective PRMT5 Inhibitors Suppress Human CD8
Strobl CD; Schaffer S; Haug T; Völkl S; Peter K; Singer K; Böttcher M; Mougiakakos D; Mackensen A; Aigner M
Mol Cancer Ther; 2020 Feb; 19(2):409-419. PubMed ID: 31712395
[TBL] [Abstract][Full Text] [Related]
10. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4.
Chandler DS; Singh RK; Caldwell LC; Bitler JL; Lozano G
Cancer Res; 2006 Oct; 66(19):9502-8. PubMed ID: 17018606
[TBL] [Abstract][Full Text] [Related]
11. PRMT5 is required for cell-cycle progression and p53 tumor suppressor function.
Scoumanne A; Zhang J; Chen X
Nucleic Acids Res; 2009 Aug; 37(15):4965-76. PubMed ID: 19528079
[TBL] [Abstract][Full Text] [Related]
12. The Fanconi anemia pathway controls oncogenic response in hematopoietic stem and progenitor cells by regulating PRMT5-mediated p53 arginine methylation.
Du W; Amarachintha S; Erden O; Wilson A; Pang Q
Oncotarget; 2016 Sep; 7(37):60005-60020. PubMed ID: 27507053
[TBL] [Abstract][Full Text] [Related]
13. Regulation of human p53 activity and cell localization by alternative splicing.
Ghosh A; Stewart D; Matlashewski G
Mol Cell Biol; 2004 Sep; 24(18):7987-97. PubMed ID: 15340061
[TBL] [Abstract][Full Text] [Related]
14. PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia.
Radzisheuskaya A; Shliaha PV; Grinev V; Lorenzini E; Kovalchuk S; Shlyueva D; Gorshkov V; Hendrickson RC; Jensen ON; Helin K
Nat Struct Mol Biol; 2019 Nov; 26(11):999-1012. PubMed ID: 31611688
[TBL] [Abstract][Full Text] [Related]
15. MDM4 is a rational target for treating breast cancers with mutant p53.
Miranda PJ; Buckley D; Raghu D; Pang JB; Takano EA; Vijayakumaran R; Teunisse AF; Posner A; Procter T; Herold MJ; Gamell C; Marine JC; Fox SB; Jochemsen A; Haupt S; Haupt Y
J Pathol; 2017 Apr; 241(5):661-670. PubMed ID: 28097652
[TBL] [Abstract][Full Text] [Related]
16. Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.
Luo Y; Gao Y; Liu W; Yang Y; Jiang J; Wang Y; Tang W; Yang S; Sun L; Cai J; Guo X; Takahashi S; Krausz KW; Qu A; Chen L; Xie C; Gonzalez FJ
Hepatology; 2021 Oct; 74(4):1932-1951. PubMed ID: 33896016
[TBL] [Abstract][Full Text] [Related]
17. PRMT5 and CDK4/6 inhibition result in distinctive patterns of alternative splicing in melanoma.
Chan LH; Wang P; Abuhammad S; Lim LRJ; Cursons J; Sheppard KE; Goode DL
PLoS One; 2023; 18(11):e0292278. PubMed ID: 37917641
[TBL] [Abstract][Full Text] [Related]
18. Dysregulation of Mdm2 and Mdm4 alternative splicing underlies motor neuron death in spinal muscular atrophy.
Van Alstyne M; Simon CM; Sardi SP; Shihabuddin LS; Mentis GZ; Pellizzoni L
Genes Dev; 2018 Aug; 32(15-16):1045-1059. PubMed ID: 30012555
[TBL] [Abstract][Full Text] [Related]
19. PRMT5 Modulates Splicing for Genome Integrity and Preserves Proteostasis of Hematopoietic Stem Cells.
Tan DQ; Li Y; Yang C; Li J; Tan SH; Chin DWL; Nakamura-Ishizu A; Yang H; Suda T
Cell Rep; 2019 Feb; 26(9):2316-2328.e6. PubMed ID: 30811983
[TBL] [Abstract][Full Text] [Related]
20. Ribosome subunit attrition and activation of the p53-MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition.
Howard GC; Wang J; Rose KL; Jones C; Patel P; Tsui T; Florian AC; Vlach L; Lorey SL; Grieb BC; Smith BN; Slota MJ; Reynolds EM; Goswami S; Savona MR; Mason FM; Lee T; Fesik S; Liu Q; Tansey WP
Elife; 2024 Apr; 12():. PubMed ID: 38682900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
